MENU
+Compare
ACXP
Stock ticker: NASDAQ
AS OF
Apr 23 closing price
Price
$0.39
Change
+$0.01 (+2.63%)
Capitalization
8.3M

ACXP Acurx Pharmaceuticals Forecast, Technical & Fundamental Analysis

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration... Show more

ACXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ACXP with price predictions
Apr 23, 2025

ACXP's RSI Oscillator ascends from oversold territory

The RSI Indicator for ACXP moved out of oversold territory on April 10, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 15, 2025. You may want to consider a long position or call options on ACXP as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ACXP just turned positive on March 25, 2025. Looking at past instances where ACXP's MACD turned positive, the stock continued to rise in of 32 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACXP advanced for three days, in of 187 cases, the price rose further within the following month. The odds of a continued upward trend are .

ACXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACXP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ACXP entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.495) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ACXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ACXP is expected to report earnings to rise 137.50% to -37 cents per share on May 08

Acurx Pharmaceuticals ACXP Stock Earnings Reports
Q1'25
Est.
$-0.38
Q4'24
Beat
by $0.02
Q3'24
Missed
by $0.02
Q2'24
Missed
by $0.09
Q1'24
Missed
by $0.04
The last earnings report on March 18 showed earnings per share of -15 cents, beating the estimate of -18 cents. With 82.06K shares outstanding, the current market capitalization sits at 8.30M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
259 Liberty Avenue
Phone
+1 917 533-1469
Employees
4
Web
https://www.acurxpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NICE151.394.32
+2.94%
NICE Ltd
EXFY2.830.06
+1.99%
Expensify
MODG6.600.04
+0.61%
Topgolf Callaway Brands Corp
DRD15.46-0.67
-4.15%
DRDGOLD Ltd
WNW2.11-0.34
-13.88%
Meiwu Technology Company Limited

ACXP and Stocks

Correlation & Price change

A.I.dvisor tells us that ACXP and ALEC have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACXP and ALEC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACXP
1D Price
Change %
ACXP100%
+3.53%
ALEC - ACXP
32%
Poorly correlated
+6.31%
SLRN - ACXP
30%
Poorly correlated
-3.85%
OTLK - ACXP
29%
Poorly correlated
+3.33%
CMMB - ACXP
29%
Poorly correlated
+2.56%
MGX - ACXP
26%
Poorly correlated
+3.82%
More